Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 2/20 | 0.42 |
| ▸ | NMT1 | P30419 | 2/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370325 | 1.00 | FOLH1 (0.58) | FOLH1NOD1SLC6A5GLO1PTGS1 | |
| SCHEMBL30099709 | 0.96 | FOLH1 (0.56) | FOLH1NOD1SLC6A5GLO1PTGS1 | |
| SCHEMBL30099563 | 0.94 | FOLH1 (0.56) | FOLH1NOD1SLC6A5GLO1PTGS1 | |
| SCHEMBL29655368 | 0.93 | FOLH1 (0.53) | FOLH1NOD1SLC6A5GLO1PTGS1 | |
| SCHEMBL30064268 | 0.93 | FOLH1 (0.48) | FOLH1GLO1PTGS1GSTK1NMT2 | |
| SCHEMBL29569049 | 0.93 | FOLH1 (0.46) | FOLH1NOD1SLC6A5NMT2NMT1 | |
| SCHEMBL30697803 | 0.93 | FOLH1 (0.59) | FOLH1NOD1SLC6A5GLO1PTGS1 | |
| SCHEMBL30099692 | 0.92 | FOLH1 (0.56) | FOLH1NOD1SLC6A5GLO1PTGS1 | |
| SCHEMBL31480035 | 0.91 | FOLH1 (0.50) | FOLH1SLC6A5GLO1PTGS1GSTK1 | |
| SCHEMBL30099585 | 0.91 | FOLH1 (0.53) | FOLH1NOD1SLC6A5GLO1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| CN-103665170-A | Peptide therapeutic conjugates and uses thereof | ANGIOCHEM INC | 2014-03-26 | — | — | CN | disclosed |
| CN-102348723-A | Peptide therapeutic agent conjugates and uses thereof | ANGIOCHEM INC | 2012-02-08 | — | — | CN | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | FOLH1 144/4885NOD1 3097/4885SLC6A5 567/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | FOLH1 144/4885NOD1 3097/4885SLC6A5 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.